Mizuho lowered the firm’s price target on Biogen (BIIB) to $207 from $251 and keeps an Outperform rating on the shares. The analyst updated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback